首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF8 |
| Uniprot No | P32971 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 63-234aa |
| 氨基酸序列 | QRTDSIPNSPDNVPLKGGNCSEDLLCILKRAPFKKSWAYLQVAKHLNKTKLSWNKDGILHGVRYQDGNLVIQFPGLYFIICQLQFLVQCPNNSVDLKLELLINKHIKKQALVTVCESGMQTKHVYQNLSQFLLDYLQVNTTISVNVDTFQYIDTSTFPLENVLSIFLYSNSD |
| 预测分子量 | 45.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF8(CD30L)重组蛋白的3篇模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **标题**: "Recombinant TNFSF8 enhances CD30-mediated T cell activation and antitumor immunity"
**作者**: Smith A, et al.
**摘要**: 研究利用重组TNFSF8蛋白证实其通过与CD30受体结合，激活NF-κB信号通路，促进T细胞增殖及细胞因子分泌，并增强抗肿瘤免疫应答的潜在机制。
2. **标题**: "Structural characterization of recombinant TNFSF8 and its binding affinity to CD30"
**作者**: Brown C, et al.
**摘要**: 通过X射线晶体学解析重组TNFSF8的三维结构，揭示其与CD30受体结合的关键表位，并通过表面等离子体共振(SPR)验证两者高亲和力相互作用。
3. **标题**: "Therapeutic potential of TNFSF8-Fc fusion protein in autoimmune disease models"
**作者**: Lee Y, et al.
**摘要**: 构建TNFSF8-Fc重组融合蛋白，在类风湿性关节炎小鼠模型中显示其通过调控调节性T细胞(Treg)功能减轻炎症反应，提示其在自身免疫疾病中的治疗价值。
---
**注**：以上文献为示例性内容，实际研究中请通过PubMed或Web of Science等平台检索真实文献。
TNFSF8. also known as CD153 or CD30 ligand (CD30L), is a member of the tumor necrosis factor superfamily (TNFSF) that plays a critical role in immune regulation and inflammatory responses. This type II transmembrane protein is primarily expressed on activated T cells, B cells, and antigen-presenting cells. It functions as a trimeric ligand that binds to its receptor CD30 (TNFRSF8), initiating downstream signaling pathways involved in T-cell activation, proliferation, and apoptosis. TNFSF8-CD30 interactions are particularly significant in mediating crosstalk between T cells and B cells, contributing to both protective immunity and pathological conditions such as autoimmune diseases and lymphoproliferative disorders.
Recombinant TNFSF8 protein is engineered to mimic the native extracellular domain (amino acids 51-239 in humans) through heterologous expression systems like mammalian cells or *E. coli*. This soluble form retains biological activity by forming functional trimers capable of receptor binding. Purification typically involves affinity chromatography (e.g., His-tag) followed by rigorous endotoxin removal and quality control via SDS-PAGE, Western blot, and functional assays.
In research, recombinant TNFSF8 serves as a tool to study CD30-mediated signaling in immune cell interactions, cancer biology (e.g., Hodgkin's lymphoma), and inflammatory diseases. It has potential therapeutic applications as a target for antibody-drug conjugates or as a component in immunotherapy strategies. Recent studies also explore its role in modulating regulatory T cells (Tregs) and cytokine production, highlighting its dual pro-inflammatory and immunosuppressive effects depending on cellular context. The development of TNFSF8 antagonists/agonists is an active area in drug discovery for autoimmune disorders and hematologic malignancies.
×
